“Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial”
- 1 July 2020
- journal article
- research article
- Published by Elsevier in Digestive and Liver Disease
- Vol. 52 (7) , 730-733
Abstract
No abstract availableKeywords
Funding Information
- Institut National Du Cancer
This publication has 14 references indexed in Scilit:
- Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectivesCancer Treatment Reviews, 2019
- Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study)Clinical Cancer Research, 2017
- A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer BiomarkerClinical Chemistry, 2016
- Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancerBMC Cancer, 2013
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012European Journal of Cancer, 2013
- Adjuvant Therapy With Fluorouracil and Oxaliplatin in Stage II and Elderly Patients (between ages 70 and 75 years) With Colon Cancer: Subgroup Analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer TrialJournal of Clinical Oncology, 2012
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon CancerJournal of Clinical Oncology, 2010
- Adjuvant Therapy for completely resected Stage II Colon CancerCochrane Database of Systematic Reviews, 2008
- Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised studyThe Lancet, 2007
- Time trends in the treatment and survival of recurrences from colorectal cancerAnnals of Oncology, 2005